A specific cytotoxic T-lymphocyte epitope presentation system for antitumor immunity
Ying Wu
State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Ying Wu and Changzhen Liu contributed equally to this work.
Search for more papers by this authorChangzhen Liu
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Ying Wu and Changzhen Liu contributed equally to this work.
Search for more papers by this authorHexiao Shen
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Search for more papers by this authorCorresponding Author
Deyin Guo
State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China
Tel: +86-27-68752506; Fax: +86-27-68752897
Deyin Guo, Modern Virology Center, National Key Lab of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
Bin Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 1, Beichen Xilu Rd, Chaoyang District, Beijing 100101, PR China
Search for more papers by this authorCorresponding Author
Bin Gao
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
China-Japan Joint Laboratory for Molecular Immunology and Virology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Tel and Fax: +86-10-64807338
Deyin Guo, Modern Virology Center, National Key Lab of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
Bin Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 1, Beichen Xilu Rd, Chaoyang District, Beijing 100101, PR China
Search for more papers by this authorYing Wu
State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Ying Wu and Changzhen Liu contributed equally to this work.
Search for more papers by this authorChangzhen Liu
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Ying Wu and Changzhen Liu contributed equally to this work.
Search for more papers by this authorHexiao Shen
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Search for more papers by this authorCorresponding Author
Deyin Guo
State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China
Tel: +86-27-68752506; Fax: +86-27-68752897
Deyin Guo, Modern Virology Center, National Key Lab of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
Bin Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 1, Beichen Xilu Rd, Chaoyang District, Beijing 100101, PR China
Search for more papers by this authorCorresponding Author
Bin Gao
The Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
China-Japan Joint Laboratory for Molecular Immunology and Virology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
Tel and Fax: +86-10-64807338
Deyin Guo, Modern Virology Center, National Key Lab of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
Bin Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 1, Beichen Xilu Rd, Chaoyang District, Beijing 100101, PR China
Search for more papers by this authorAbstract
The magnitude of CTL-mediated immunity response is highly dependent on the density of antigenic peptide–MHC I complexes at the cell surface. In this study, we adopt a novel strategy to promote the surface level of specific peptide–MHC I complexes. The strategy combines the inhibition of transporter associated with antigen processing (TAP) with the delivery of specific peptide into endoplasmic reticulum directly without the help of TAP. First, RNA interference (RNAi) technology was used to inhibit TAP expression for blocking endogenous epitope-assembled MHC class I on cell surface. Second, a peptide epitope of interest was covalently linked onto human beta-2-microglobulin (β2m). Both TAP-specific siRNA and the peptide-linked β2m were delivered into antigen-presentation cells sequentially or simultaneously using a retrovirus delivery system. The combined strategy produces a significant amount of MHC I loaded with specific epitopes on the surface while reducing endogenously peptide-assembled MHC class I both in vitro and in vivo. The efficacy of induction of specific immune response with the strategy against tumor cells is demonstrated in both tumor cell lines and a syngenic graft tumor model.
References
- 1 Momburg F, Hammerling GJ. Generation and TAP-mediated transport of peptides for major histocompatibility complex class I molecules. Adv Immunol 1998; 68: 191–256.
- 2 Cresswell P, Lanzavecchia A. Antigen processing and recognition. Curr Opin Immunol 2001; 13: 11–12.
- 3 Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2002; 82: 187–204.
- 4 Powis SJ, Townsend AR, Deverson EV, Bastin J, Butcher GW, Howard JC. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature 1991; 354: 528–31.
- 5 Norbury CC, Princiotta MF, Bacik I, Brutkiewicz RR, Wood P, Elliott T, Bennink JR, Yewdell JW. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol 2001; 166: 4355–62.
- 6 Trucco M, de Petris S, Garotta G, Ceppellini R. Quantitative analysis of cell surface HLA structures by means of monoclonal antibodies. Hum Immunol 1980; 1: 233–43.
- 7 Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716–19.
- 8 Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994; 12: 181–207.
- 9 Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 1994; 180: 1283–93.
- 10 Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996; 183: 2403–7.
- 11 Levitsky V, Zhang QJ, Levitskaya J, Masucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 1996; 183: 915–26.
- 12 Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075–82.
- 13 Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169–78.
- 14 Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199: 251–63.
- 15 Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, Hildebrand WH, Lustgarten J. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 2006; 177: 5088–97.
- 16 Mottez E, Langlade-Demoyen P, Gournier H, Martinon F, Maryanski J, Kourilsky P, Abastado JP. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. J Exp Med 1995; 181: 493–502.
- 17 Kang X, Robbins PF, Fitzgerald EB, Wang R, Rosenberg SA, Kawakami Y. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Res 1997; 57: 202–5.
- 18 Uger RA, Barber BH. Creating CTL targets with epitope-linked beta 2-microglobulin constructs. J Immunol 1998; 160: 1598–605.
- 19 Tafuro S, Meier UC, Dunbar PR, Jones EY, Layton GT, Hunter MG, Bell JI, McMichael AJ. Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules. Eur J Immunol 2001; 31: 440–9.
- 20 Yu YY, Netuschil N, Lybarger L, Connolly JM, Hansen TH. Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol 2002; 168: 3145–9.
- 21 Lybarger L, Yu YY, Miley MJ, Fremont DH, Myers N, Primeau T, Truscott SM, Connolly JM, Hansen TH. Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J Biol Chem 2003; 278: 27105–11.
- 22 Margalit A, Sheikhet HM, Carmi Y, Berko D, Tzehoval E, Eisenbach L, Gross G. Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin. J Immunol 2006; 176: 217–24.
- 23 Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6: 715–26.
- 24
Lewis JW, Sewell A, Price D, Elliott T.
HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin.
Eur J Immunol
1998;
28:
3214–20.
10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 25 Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777–85.
- 26 Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A. 1992; 89: 6020–4.
- 27 Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693–702.
- 28 Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004; 122: 131–39.
- 29 Sanderson S, Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 1994; 6: 369–76.
- 30 Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 2007; 325: 51–66.
- 31 Kumar R, Yoneda J, Fidler IJ, Dong Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol 1999; 65: 102–8.
- 32 Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S, Matory Y, Skibber J, Shiloni E, Vetto J. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
- 33 Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991; 174: 489–92.
- 34 Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986; 5: 943–9.
- 35 Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675–78.
- 36 De Bruijn ML, Schumacher TN, Nieland JD, Ploegh HL, Kast WM, Melief CJ. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol 1991; 21: 2963–70.
- 37 Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–96.
- 38 Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, Banchereau J. B70/B7–2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180: 1841–7.
- 39 Langiade-Demoyen P, Levraud J-P, Kourilsky P, Abastado J-P. Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int Immunol 1994; 6: 1759–66.
- 40 Leifert JA, Rodriguez-Carreno MP, Rodriguez F, Whitton JL. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 2004; 199: 40–53.
- 41 Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–5.
- 42 Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, Tampe R, Peterson PA, Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415–18.
- 43 Hengel H, Flohr T, Hammerling GJ, Koszinowski UH, Momburg F. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC Class I assembly. J Gen Virol 1996; 77: 2287–96.
- 44 Radosevich TJ, Seregina T, Link CJ. Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure. Hum Gene Ther 2003; 14: 1765–75.
- 45 Berko D, Carmi Y, Cafri G, Ben-Zaken S, Sheikhet HM, Tzehoval E, Eisenbach L, Margalit A, Gross G. Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules. J Immunol 2005; 174: 2116–23.
- 46 Nakamura K, Zuppini A, Arnaudeau S, Lynch J, Ahsan I, Krause R, Papp S, De Smedt H, Parys JB, Muller-Esterl W, Lew DP, Krause K-H, et al. Functional specialization of calreticulin domains. J Cell Biol 2001; 154: 961–72.
- 47 Shields MJ, Moffat LE, Ribaudo RK. Functional comparison of bovine, murine, and human [beta]2-microglobulin: interactions with murine MHC I molecules. Mol Immunol 1998; 35: 919–28.
- 48 Pedersen LO, Stryhn A, Holter TL, Etzerodt M, Gerwien J, Nissen MH, Thogersen HC, Buus S. The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur J Immunol 1995; 25: 1609–16.
- 49 Gakamsky DM, Bjorkman PJ, Pecht I. Peptide interaction with a class I major histocompatibility complex-encoded molecule: allosteric control of the ternary complex stability. Biochemistry 1996; 35: 14841–8.
- 50 Sigal LJ, Reiser H, Rock KL. The role of B7–1 and B7–2 costimulation for the generation of CTL responses in vivo. J Immunol 1998; 161: 2740–5.
- 51 Azuma M, Lanier LL. The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 1995; 198: 59–74.
- 52
Motta I, Lone YC, Kourilsky P.
In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density.
Eur J Immunol
1998;
28:
3685–95.
10.1002/(SICI)1521-4141(199811)28:11<3685::AID-IMMU3685>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 53 Zhang QJ, Li XL, Wang D, Huang XC, Mathis JM, Duan WM, Knight D, Shi R, Glass J, Zhang DQ, Eisenbach L, Jefferies WA Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses. PLoS One 2008; 3: e3097.
- 54
Nicholl M, Lodge A, Brown I, Sugg SL, Shilyansky J
Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.
J Pediatr Surg
2004;
39:
941–6; discussion: 41–6.
10.1016/j.jpedsurg.2004.02.049 Google Scholar
- 55 Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253–66.
- 56 Bueler H, Mulligan RC. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7–1. Mol Med 1996; 2: 545–55.
- 57 Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006; 29: 233–40.
- 58 Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115–22.
- 59 Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989; 169: 1961–76.
- 60 Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 1990; 145: 2359–64.
- 61 Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004; 101: 14639–45.
- 62 Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444–53.
- 63 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–9.
- 64 Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862–71.
- 65 Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–8.
- 66 Kanold J, Paillard C, Tchirkov A, Merlin E, Marabelle A, Lutz P, Rousseau R, Baldomero H, Demeocq F. Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 2008; 42 Suppl 2: S25–S30.
- 67 Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, Kapoor N, Guinan EC, Feig SA, Wagner EL, Kernan NA. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112: 4318–27.
- 68 Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–76.
- 69 Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM. Report from the International Bone Marrow Transplant rRegistry and Autologous Blood and Marrow Transplant Registry—North America. Clin Transpl 1995: 117–27.
- 70 Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol 2003; 46: 139–63.
- 71 North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector of T cells. J Exp Med 1986; 164: 1652–66.
- 72 Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989; 49: 1649–54.
- 73 Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201: 1591–602.
- 74 Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64: 4328–37.
- 75 Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002; 8: 2690–5.
- 76 Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006; 5: 233–47.
- 77 Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007; 8: 2–3.
- 78 Kitawaki T, Kadowaki N, Kondo T, Ishikawa T, Ichinohe T, Teramukai S, Fukushima M, Kasai Y, Maekawa T, Uchiyama T. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol 2008; 83: 315–17.
- 79 Dullaers M, Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 2006; 8: 3–17.
Citing Literature
